Background: Oestrogen receptor (ER) β agonists have been demonstrated to possess
Introduction
Asthma is a chronic inflammatory disease of the lung characterised by reversible airflow obstruction, airway hyper-responsiveness and airway inflammation (Bousquet et al, 2000) . Most asthmatics are effectively treated using a combination of β 2 -adrenergic receptor agonists to relieve the constriction and corticosteroids to suppress inflammation (Bousquet et al, 2000) . However, a small proportion of asthmatics have severe or corticosteroid insensitive asthma which is poorly controlled by corticosteroids causing a reduced quality of life and imposing a considerable cost burden on health services (Ito et al, 2006; Moore & Peters, 2006) . Moreover, there are also concerns about the systemic effects of long term corticosteroid treatment (Barnes, 1993) . Thus, there is a desperate need for novel anti-inflammatory asthma therapies.
Corticosteroids elicit their actions by binding the glucocorticoid receptor (GR), which
is one of the 48, mostly, ligand activated transcription factors of the nuclear receptor super family (Gronemeyer et al, 2004) . Nuclear receptors have proved amenable targets for small molecular weight pharmacological agents that modulate their activity and there is considerable interest in the effect of modulating nuclear receptor activity in a number of diseases (Gronemeyer et al, 2004) . The pharmacological modulation of oestrogen receptor (ER) activity has proved therapeutically valuable for hormone therapy and the treatment of cancer (Shang, 2006; Vogelvang et al, 2004) . Recent reports have also indicated that activation of ER may be beneficial in treating diseases with an inflammatory component (Harris et al, 2003; Harris, 2006) . Although one caveat is that asthma is more prevalent in women which might suggest that high levels of ER activation via endogenous estrogen could be pro-asthmatic (Melgert et al, 2007) .
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In rats ERα agonists are able to mediate most of the classical effects of oestrogen such as increased uterine wet weight, maintenance of bone mineral density and vasomotor stability Hillisch et al, 2004) . Furthermore, estrogen/estradiol has been shown to be anti-inflammatory in various models of allergic asthma through an effect mediated by activation of the ERα receptor (Haggerty et al, 2003; Dgeano et al, 2001; Carey et al, 2007; Matsubara et al, 2007) .
In contrast, ERβ selective agonists, such as ERB-041, are incapable of producing the classical oestrogen responses (Harris et al, 2003) but are able to produce benefit in models of adjuvant induced arthritis and inflammatory bowel disease (Harris et al, 2003) . The ERβ agonist WAY-202196 also increased survival in rodent models of septic shock (Cristofaro et al, 2006) . Since, ERβ agonists have demonstrated utility in models of disease with an inflammatory component we postulated that an ERβ agonist could be beneficial for the treatment of asthma through the suppression of the associated inflammation thought to drive the pathogenesis of the disease (Cristofaro et al, 2006; Harris et al, 2003) . Therefore, the aim of this novel study was to determine the effects of an ERβ agonist in characterised in vitro and in vivo pre-clinical models of asthma-like inflammation. We initiated our investigation by first developing and validating assays to measure the mRNA expression of ERβ in our cell based assay systems. From this data we selected a cell type shown to express the receptor, confirmed the expression of the receptor at the protein level and then profiled the impact of ERB-041 (7-ethenyl-2-(3-fluoro-4-hydroxyphenyl)-1,3-benzoxazol-5-ol), and a number of other selective tool compounds, on IL-1β-induced inflammation. The temporal modulation of ERβ mRNA expression in the lungs of our fully characterised rodent model of allergic asthma not only demonstrated the presence of the receptor in the target organ but also encouraged us to continue with the profiling of the selective JPET #136275 6 ligand. This study is the first such study to investigate the effects of a selective ERβ agonist in human and rodent models of asthma-like inflammation.
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Methods
ERβ mRNA expression in human and rat tissues.
Validation of assay:
cDNA was prepared from RNA extracted from a panel of human tissues (Clontech Laboratories) and a parallel panel collected from 3 male Brown Norway rats g, this strain was chosen because it is the same as used in our asthma model) as previously described (Birrell et al, 2005) . Amplification of the cDNA and detection of target PCR product was carried out by Real-Time PCR using pre-developed assays (Applied Biosystems, Warrington, UK). Reactions were internally controlled with the 18S rRNA internal control as previously described (Birrell et al, 2005) . Results were analysed using the Sequence Detection Software and the relative amount of target gene transcript was normalised to the amount of 18S rRNA internal control transcript in the same cDNA sample. The data were then converted from the exponential form into linear data by using the calculation 2 -(target ct -18S ct) and then arbitrarily multiplied by 10 6 to change the values into whole numbers. The assay was then validated according to instructions from Applied Biosystems using a tissue type (human and rat) highly expressing ERβ mRNA. Assay validations were performed to ensure that the threshold cycles (ct) of both the target and internal control, determined in the linear exponential phase of the amplifications, had equal efficiencies.
ERβ expression in cells used in our in vitro inflammatory assay systems.
ERβ mRNA expression was assessed in human cells (primary airway smooth muscle cells, lung tissue macrophages and epithelial cells plus monocyte (THP-1) and epithelial (A549) cell lines) we have previously characterised using the developed and validated assay described above.
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Having shown that human airway smooth muscle (HASM) cells express ERβ at the gene level we used Western analysis (Catley et al, 2006) to show presence of the receptor at the protein level. ERβ antibody used was from Upstate/Chemicon (product number #05-824).
ERβ mRNA expression after antigen challenge in our characterised rat model of asthma.
Samples of lung tissue were collected 2, 4, 6, 8, 12 or 24 hours after vehicle or antigen challenge. Level of mRNA expression was measured using the validated assay described above.
Effect of ER agonists in cultured human airway smooth muscle cells.
HASM cells were isolated from normal lung transplant donor tissue surplus to requirement and cultured as previously described (Belvisi et al, 1997) . Consent from relatives and ethical approval were obtained. Cells were rinsed with fresh medium (Dulbecco's Modified Eagle's Medium (DMEM, Gibco, UK) plus supplements as previously described) and treated with indomethacin (10 -5 M, Sigma UK) for 30 minutes, and throughout the study, to block endogenous cyclo-oxygenase activity which can impact on cytokine production (Lazzeri et al, 2001) . M, Sigma, UK) was included as an intra-assay control. Twenty-four hours after stimulation, the supernatants were collected and stored at -20°C, cells were then assayed for cell viability by MTT assay. Cytokine levels in the supernatants were determined by ELISA (R&D systems, UK). Ovalbumin (Sigma, UK) sensitisation and challenge in this model has previously been described (Birrell et al, 2005) . For this study there were two parallel arms, the first entailed collecting plasma and lung tissue samples six hours after the OVA challenge. The second arm of the study was designed to measure the level of airway eosinophilia in the airway lumen and lung tissue 24 hours after challenge (as described in 14). Where appropriate rats were orally dosed (5 ml/kg) with vehicle (1% DMSO:66% PEG:33% H 2 0) or compounds (ERB-041 at 3, 10 and 30 mg/kg) 1 hour before and 1 and 6 hours after challenge. Budesonide (3 mg/kg) was included as a positive control (14).
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Plasma levels of ERB-041 (n.b. 5 hours after last oral dose) were determined using liquid chromatography tandem mass spectrometry. ERβ activation was demonstrated by measuring IGFBP4 mRNA expression, believed to be linked to ligand binding to this receptor (Harris et al, 2003) , using the real-time RT-PCR technique outlined above.
Results
ERβ expression
Using the validated real-time PCR assay we demonstrated that, under these conditions, primary HASM and epithelial cells expressed ERβ mRNA to a greater extent compared to the other cell types tested ( Figure 1A ). Of the two cell types shown to express ERβ; at the mRNA level it was decided to choose HASM cells to further our work as this cell is known to be central to pathogenesis of asthma (Oliver & Black, 2006) and has been well characterised in our group (Birrell et al, 2005; Catley et al, 2006; Belvisi et al, 1997) . Having shown the presence of the receptor at the mRNA level we wanted to ensure this corresponded to expression at the protein level before continuing with profiling the selective ligands. Figure 1B clearly shows a band on a Western blot which corresponds to the molecule weight for this receptor suggesting that ERβ is indeed expressed at the protein level in these primary cells. 
Effect of the ERβ agonist on antigen-induced allergic airway inflammation in the rat
To check for adequate compound exposure we measured plasma levels and showed that using this dosing regimen there was linear, dose related compound exposure and even 5 hours after the last oral dose there were levels in excess of 1 µM (= 300 ng/ml, at 30 mg/kg) in the plasma ( Figure 4A ). Furthermore, the IC 50 for ERB-041 binding to the rat ERβ ligand binding domain is 3.1 nM and ERB-041 is able to increase the expression of the ER responsive gene IGFBP4 with an ED 50 of 20nM in cultured SAOA-2 cells expressing the ERβ receptor (Harris et al, 2003) . Therefore, the PK data shows that systemic levels of ERB-041 were sufficient to activate ERβ in the lung. To confirm there was sufficient exposure to elicit a functional effect in vivo, IGFBP4 mRNA expression in the rat lung was used as a marker of ERβ activation (Harris et al, 2003) . The expression of IGFBP4 in the lung tissue was up regulated by
JPET #136275
12 the top dose of ERB-041 used at this time point, indicating that there is sufficient compound exposure in the lung to activate ERβ ( Figure 4B ).
The positive pharmacokinetic and pharmacodynamic data encouraged us to continue with the investigation. At the 24hr end point we showed that ovalbumin challenge caused significant eosinophilia in the BALF ( Figure 5A ) and lung tissue ( Figure 5B) of sensitised rats. The numbers of eosinophils in the BALF and tissue were significantly reduced by treatment with budesonide at 3 mg/kg ( Figure 5 ). However, treatment with ERB-041 had no significant effect on the eosinophilia in the BALF ( Figure 5A ) or lung tissue ( Figure 5B ).
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Discussion
ERβ agonists have demonstrated utility in models of disease with an inflammatory component therefore we postulated that an ERβ agonist could be beneficial for the treatment of asthma through the suppression of the associated inflammation thought to drive the pathogenesis of the disease (Haggerty et al, 2003; Cristofaro et al, 2006; Harris et al, 2003) . The aim of this study was to determine the effects of an ERβ agonist in characterised in vitro and in vivo pre-clinical models of asthma-like inflammation. The initial results were promising insomuch as we were able to show that HASM cells expressed the target receptor, ERβ, at the mRNA and protein level.
In parallel with this we found that ERβ expression was reduced by ovalbumin challenge in our pre-clinical rat model of asthma. The timing of the reduction of ERβ expression corresponds with key processes in the ovalbumin induced inflammatory response, such as the induction of inflammatory cytokine gene expression at 6 hours and the influx of immune cells at 24 hours (Underwood et al, 2002) . This data indicates that reduction of ERβ expression may be an important process in the development of inflammation in the rat lung after ovalbumin challenge. Thus it seemed possible that agonist induced activation of ERβ receptors may ameliorate effects of antigen challenge and reduce the inflammatory response. When, however, we profiled the impact of various ligands in the human cell based assay and the selective ERβ agonist in the pre-clinical model of asthma we failed to observe any anti-inflammatory activity. The demonstration that ERβ agonists were effective in models of inflammatory bowel disease and arthritis raised the possibility that ERβ agonists could be used to treat a range of inflammatory diseases including asthma (Harris et al, 2003; Harris, 2006) . However, the data presented here demonstrates for the first time that, although ERβ receptors are expressed in the lung, agonists have no
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14 effect on inflammation. The data presented here is on the whole negative but makes an important addition to the literature regarding ERβ agonists in inflammatory disease. Our data, however does not rule out any impact on airway smooth muscle hypertrophy/hyperplasia as suggested by others (Hughes et al 2002) . Indeed, considerable data has been published regarding the positive effects of ERβ agonists in certain models of inflammatory disease (Cristofaro et al, 2006; Harris et al, 2003; Cristofaro et al, 2006; Follettie et al, 2006; Harris, 2006) . However, a recent review indicated that ERβ agonists are ineffective in a range of inflammatory models including collagen induced arthritis (Harris, 2006) . Unfortunately, none of this data has been peer reviewed and published and the experimental details are not available for critical evaluation. Thus the data presented here is one of the first published accounts demonstrating the lack of effect of an ERβ agonist in an inflammatory airway disease. This is important since it demonstrates that ERβ agonists are not general anti-inflammatory agents but have some beneficial effects in certain models of inflammatory diseases and not in others.
Several studies have indicated that estrogenic compounds have a positive effect in lung disease and in animal models (Speyer et al, 2005; Cuzzocrea et al, 2001; Shirai et al, 1995; Degano et al, 2001; Carey et al, 2007; Matsubara et al, 2007) . These have looked at either the effect of pregnancy on inflammatory lung disease in humans or the effect of oestrogen administration to ovariectomised female mice or the effect of ovariectomy on lung inflammation. None have used selective agonists of the individual ERs (Haggerty et al, 2003) . It is therefore possible that some of these positive effects were mediated through ERα which has documented antiinflammatory properties in some in vivo models (Harris, 2006) . The fact that ERβ agonists are effective in models of IBD and arthritis but not other inflammatory disease may represent fundamental differences between the inflammatory responses present in these diseases. There is data to suggest that oestrogen promotes a Thelper(Th)-2 cytokine profile and this is why some Th-1 driven disease including arthritis show some improvement during pregnancy when oestrogen levels are high (Doria et al, 2006) . Conversely, there is evidence that Th-2 driven diseases such as systemic lupus erythematosus show increased flare up during pregnancy (Doria et al, 2006 Sensitised BN rats were dosed with ERB-041 and then challenged with ovalbumin.
Plasma levels 5 hours after the last oral dose and levels of compound determined (A)
The expression of IGFBP4 mRNA (marker of ERβ activation) in the lung tissue 5 hours after the last oral dose measured using RT-PCR (B). Data (n=8) is expressed as means ± s.e.mean. 
